|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
This article explains the key changes that pharmaceutical companies and CMOs engaged in manufacturing and fill-finish need to consider, as well as what AbbVie Contract Manufacturing (AbbVie CMO) is doing to ensure its global operations and aseptic fill-finish sites are in compliance with the revised regulations….
|
|
 |
|
This 30-page eBook is exactly what you have been looking for. Find out what is driving the lyophilization market and how working with a CDMO will save time and money and help you comply with increasing regulatory requirements.
|
|
 |
|
Thanks to our many GMP manufacturing sites located in North America, Europe and Asia we can provide the critical ingredients for your Biopharma manufacturing applications.
|
|
|
|
|
|
|
|
|
Contributor Cindy H. Dubin speaks with several leading companies to discuss novel and functional excipients being developed, the role they will play in reformulations and new formulations, and their versatility in drug delivery.
|
|
|
Nicholas DiFranco, MEM, believes by working alone or alongside other well-established excipients for controlled release such as HPMC, the power of carbomer chemistry can help drug developers to overcome common challenges associated with controlled-release formulations without resorting to more complex techniques.
|
|
|
Carin Siow, PhD, explains how the progress to tackle the root causes of medication mis-use has been frustratingly slow and believes the pharma industry’s secret weapon in the fight against non-compliance are functional excipients.
|
|
|
Jim Huang, PhD, and Shaukat Ali, PhD, focus on the chemistry, properties, applications, and regulatory aspects of PLGA, and the future trends in the industry, especially those requiring the development of long-acting injectables for the treatment of a variety of rare diseases and for life cycle management.
|
|
|
Joey Glassco, MBA, says the power of novel excipients such as Apisolex polymer could revolutionize the parenteral drug development landscape, effectively solubilizing a wide range of APIs without compromising on safety or stability.
|
|
|
|
|
|
|
|
|

Agno Pharmaceuticals is a leading, global, small molecule Contract Development and Manufacturing Organization (CDMO), catering to the specific needs of the branded pharmaceutical, biotech, generic, and CDMO sectors. Agno Pharmaceuticals is a US-based, end-to-end premier service provider. We specialize in supplying Registered Starting Materials (RSMs), custom Chemical Intermediates, Active Pharmaceutical Ingredients (APIs), highly potent APIs, sterile APIs, and complex Drug Product formulations (including long-acting injectables/implants) to our valued clientele worldwide. Our US-FDA inspected cGMP compliant manufacturing facilities ensures that we are able to provide our services at a level of unparalleled quality and compliance to our customer base. Click here for more.
|
|
|
|
|
|
 |
|
Abstract: A team of bioavailability experts at Catalent used the in-house bioavailability enhancement platform, OptiForm® Solution Suite, to optimize and develop Phase 1 clinical formulation within a short timeline. Catalent’s global supply chain expertise was utilized for packaging and distributing …
|
|
 |
|
By: Sabrina Metze, PhD, Ulrich Klöckner, PhD, Lars Geiger, PhD, Justin Schieven, PhD, and Thomas Böhmer*
Summary
The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. Packer et al. have identified …
|
|
 |
|
Traditionally, lipid-based drug delivery, including SEDDS, for per-oral dosing have primarily been formulated as soft-gels or liquid-filled hard-gels. With ABISORB-DC, the bioavailability enhancing features of lipid-based drug delivery can be combined with the high-throughput and ease of manufacturing of direct …
|
|
 |
|
Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at the desired site of action.
Download our latest white paper, jointly authored with MeltPrep, to …
|
|
|
|
|
Upcoming eNewsletter Features:
July 3 – Controlled Release
July 10 – Analytical Testing
|
|
|
|
|
|
|
|